507 related articles for article (PubMed ID: 7151338)
1. Biological significance of the C3 nephritic factor in membranoproliferative glomerulonephritis.
Schena FP; Pertosa G; Stanziale P; Vox E; Pecoraro C; Andreucci VE
Clin Nephrol; 1982 Nov; 18(5):240-6. PubMed ID: 7151338
[TBL] [Abstract][Full Text] [Related]
2. Production of nephritic factor of the alternative complement pathway by Epstein Barr virus-transformed B cell lines derived from a patient with membranoproliferative glomerulonephritis.
Hiramatsu M; Balow JE; Tsokos GC
J Immunol; 1986 Jun; 136(12):4451-5. PubMed ID: 3011894
[TBL] [Abstract][Full Text] [Related]
3. C3 nephritic factor and C4 nephritic factor in the serum of two patients with hypocomplementaemic membranoproliferative glomerulonephritis.
Tanuma Y; Ohi H; Watanabe S; Seki M; Hatano M
Clin Exp Immunol; 1989 Apr; 76(1):82-5. PubMed ID: 2736802
[TBL] [Abstract][Full Text] [Related]
4. Selective disappearance of C3NeF IgG autoantibody in the plasma of a patient with membranoproliferative glomerulonephritis following renal transplantation.
Frémeaux-Bacchi V; Weiss L; Brun P; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(7):811-4. PubMed ID: 7970124
[TBL] [Abstract][Full Text] [Related]
5. C3 nephritic factor (C3NeF): dissociation of cell-bound and fluid phase stabilization of alternative pathway C3 convertase.
Ng YC; Peters DK
Clin Exp Immunol; 1986 Aug; 65(2):450-7. PubMed ID: 3641695
[TBL] [Abstract][Full Text] [Related]
6. Two types of C3 nephritic factor: properdin-dependent C3NeF and properdin-independent C3NeF.
Tanuma Y; Ohi H; Hatano M
Clin Immunol Immunopathol; 1990 Aug; 56(2):226-38. PubMed ID: 2143128
[TBL] [Abstract][Full Text] [Related]
7. C3 nephritic factor and hypocomplementaemia in a clinically healthy individual.
Gewurz AT; Imherr SM; Strauss S; Gewurz H; Mold C
Clin Exp Immunol; 1983 Oct; 54(1):253-8. PubMed ID: 6616970
[TBL] [Abstract][Full Text] [Related]
8. [Complement and nephritic activity in membranoproliferative glomerulonephritis].
Lévy M; Sich M; Habib R
Arch Fr Pediatr; 1979 Nov; 36(9 Suppl):LXIV-LXXIV. PubMed ID: 539879
[TBL] [Abstract][Full Text] [Related]
9. Occurrence of C3 nephritic factor and C4 nephritic factor in membranoproliferative glomerulonephritis (MPGN).
Ohi H; Yasugi T
Clin Exp Immunol; 1994 Feb; 95(2):316-21. PubMed ID: 8306508
[TBL] [Abstract][Full Text] [Related]
10. Hereditary and acquired complement dysregulation in membranoproliferative glomerulonephritis.
Licht C; Fremeaux-Bacchi V
Thromb Haemost; 2009 Feb; 101(2):271-8. PubMed ID: 19190809
[TBL] [Abstract][Full Text] [Related]
11. Hypocomplementaemia of poststreptococcal acute glomerulonephritis is associated with C3 nephritic factor (C3NeF) IgG autoantibody activity.
Frémeaux-Bacchi V; Weiss L; Demouchy C; May A; Palomera S; Kazatchkine MD
Nephrol Dial Transplant; 1994; 9(12):1747-50. PubMed ID: 7708258
[TBL] [Abstract][Full Text] [Related]
12. Pathways of complement activation in membranoproliferative glomerulonephritis and allograft rejection.
Fearon DT; Daha MR; Strom TB; Weiler JM; Carpenter CB; Austen KF
Transplant Proc; 1977 Mar; 9(1):729-39. PubMed ID: 325806
[TBL] [Abstract][Full Text] [Related]
13. Identification of nephritic factor as an immunoglobulin.
Williams DG; Bartlett A; Duffus P
Clin Exp Immunol; 1978 Sep; 33(3):425-9. PubMed ID: 104814
[TBL] [Abstract][Full Text] [Related]
14. Unraveling the Molecular Mechanisms Underlying Complement Dysregulation by Nephritic Factors in C3G and IC-MPGN.
Donadelli R; Pulieri P; Piras R; Iatropoulos P; Valoti E; Benigni A; Remuzzi G; Noris M
Front Immunol; 2018; 9():2329. PubMed ID: 30487789
[TBL] [Abstract][Full Text] [Related]
15. [Direct detection C3bBb stabilizing activity in sera from hypocomplementaemic membranoproliferative glomerulonephritis (MPGN) and complement profiles of C3NeF positive cases].
Watanabe S; Ohi H; Seki M; Fujita T; Hatano M
Nihon Jinzo Gakkai Shi; 1985 Oct; 27(10):1345-52. PubMed ID: 4094159
[No Abstract] [Full Text] [Related]
16. Significance of C3 nephritic factor (C3NeF) in non-hypocomplementaemic serum with membranoproliferative glomerulonephritis (MPGN).
Ohi H; Watanabe S; Fujita T; Yasugi T
Clin Exp Immunol; 1992 Sep; 89(3):479-84. PubMed ID: 1516262
[TBL] [Abstract][Full Text] [Related]
17. [Partial lipodystrophy, hypocomplementemia and glomerulonephritis].
Habib R; Lévy M; Gubler MC; Broyer M; Habib M
Arch Fr Pediatr; 1977; 34(7 Suppl):CXCVII-CCXII. PubMed ID: 931525
[TBL] [Abstract][Full Text] [Related]
18. [Complement activating factors in hypocomplementemic membranoproliferative glomerulonephritis (MPGN) patients' sera--comparison with C3NeF positive and negative cases].
Ohmori F; Ohi H; Seki M; Watanabe S; Hatano M
Nihon Jinzo Gakkai Shi; 1987 Apr; 29(4):493-8. PubMed ID: 3656707
[No Abstract] [Full Text] [Related]
19. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome.
Servais A; Frémeaux-Bacchi V; Lequintrec M; Salomon R; Blouin J; Knebelmann B; Grünfeld JP; Lesavre P; Noël LH; Fakhouri F
J Med Genet; 2007 Mar; 44(3):193-9. PubMed ID: 17018561
[TBL] [Abstract][Full Text] [Related]
20. Autoimmune forms of thrombotic microangiopathy and membranoproliferative glomerulonephritis: Indications for a disease spectrum and common pathogenic principles.
Skerka C; Licht C; Mengel M; Uzonyi B; Strobel S; Zipfel PF; Józsi M
Mol Immunol; 2009 Sep; 46(14):2801-7. PubMed ID: 19640589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
